Irinotecan (Conventional) and Sorafenib

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

SORAfenib may interfere with the normal clearance of irinotecan from the body. This may increase side effects such as nausea, vomiting, abdominal pain, diarrhea (which can lead to dehydration and kidney failure if severe), mouth sores, lung or breathing problems, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with sorafenib may increase the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. The proposed mechanism is sorafenib inhibition of CYP450 3A4 and UGT1A1, the enzymes responsible for the metabolic clearance of irinotecan and SN-38, respectively. Concomitant treatment with sorafenib has been reported to increase irinotecan systemic exposure (AUC) by 26% to 42% and SN-38 systemic exposure by 67% to 120%. The clinical significance of these changes is unknown.

MANAGEMENT: Sorafenib product labeling recommends caution during coadministration with irinotecan. High plasma levels of irinotecan and SN-38 may result in increased toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.

Irinotecan (Conventional)

Generic Name: irinotecan

Brand name: Camptosar

Synonyms: Irinotecan

What is Irinotecan (Conventional)?

Sorafenib

Generic Name: sorafenib

Brand name: Nexavar

Synonyms: SORAfenib

What is Sorafenib?